111 studies found for:    NIAID | Open Studies | HIV/AIDS
Show Display Options
Rank Status Study
21 Unknown  Resistance to HIV Infection
Condition: HIV Infections
Intervention:
22 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
23 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
24 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
25 Not yet recruiting Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01;   Drug: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
26 Not yet recruiting Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
27 Recruiting Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies
Conditions: Blood Component Removal;   Human Immunodeficiency Virus
Intervention:
28 Unknown  Women's Interagency HIV Study (WIHS)
Condition: HIV Infections
Intervention:
29 Not yet recruiting Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Condition: HIV Infections
Interventions: Drug: Maraviroc;   Drug: Placebo
30 Recruiting Cardiometabolic Effects of Eplerenone in HIV Infection
Conditions: Cardiac Steatosis;   Hepatic Steatosis
Intervention: Drug: Inspra /Eplerenone
31 Recruiting Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants
Condition: HIV Infections
Intervention: Biological: VRC01
32 Not yet recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
33 Recruiting Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Losartan;   Drug: Placebo
34 Recruiting Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Children Infected With HIV and TB
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: Raltegravir
35 Not yet recruiting Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo for DNA/NYVAC/AIDSVAX
36 Recruiting Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Efavirenz;   Drug: Raltegravir
37 Recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
38 Not yet recruiting Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Maraviroc
39 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir
40 Recruiting Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Condition: HIV Infections
Interventions: Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years